ANNX · Healthcare
Annexon Inc
19/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ANNEXON INC
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with…
Who's behind the signal
Every informed buyer we can see on ANNX, across all three feeds.
Hedge funds · 5
Point72 (Steve Cohen)
Increased +404%
Citadel Advisors
Increased +118%
Millennium Management (Englander)
Decreased −56%
D.E. Shaw & Co
Decreased −33%
AQR Capital Management
Unchanged
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ANNEXON INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
2
Increasing
2
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+404%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+118%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−56%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−33%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
—
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ANNEXON INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ANNEXON INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订